Evidence map›Paper›PMID 34681228›Full record

ArticlePharmaceuticals (Basel, Switzerland)2021

Lipid-Lowering Bioactivity of Microalga

Bingbing Guo, Yonghui Zhou, Bin Liu, Yongjin He, Feng Chen, Ka-Wing Cheng

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Bingbing GuoFaculty of Environment and Life, Beijing University of Technology, 100 Pingleyuan, Chaoyang District, Beijing 100124, China.ORCID 0000-0003-3471-168X
Yonghui ZhouFaculty of Environment and Life, Beijing University of Technology, 100 Pingleyuan, Chaoyang District, Beijing 100124, China.
Bin LiuShenzhen Key Laboratory of Marine Microbiome Engineering, Institute for Advanced Study, Shenzhen University, Nanshan District, Shenzhen 518060, China.
Yongjin HeCollege of Life Sciences, Fujian Normal University, No.1, Keji Road, Fuzhou 350117, China.
Feng ChenShenzhen Key Laboratory of Marine Microbiome Engineering, Institute for Advanced Study, Shenzhen University, Nanshan District, Shenzhen 518060, China.ORCID 0000-0002-9054-943X
Ka-Wing ChengShenzhen Key Laboratory of Marine Microbiome Engineering, Institute for Advanced Study, Shenzhen University, Nanshan District, Shenzhen 518060, China.
Shenzhen University · CNBeijing University of Technology · CNFujian Normal University · CN

Funding

China Postdoctoral Science Foundation 2019M660383Guangdong Province Zhujiang Talent Program 2019ZT08H476Key-Area Research and Development Program of Guangdong Province 2018B020206001, 2019B020212001Shenzhen Science and Technology Program KQTD20180412181334790
6 · The paper itself

Abstract

Non-alcoholic fatty liver disease (NAFLD), characterized by hepatic steatosis, is one of the most common liver diseases worldwide. So far, no definitive medical treatment has been established to treat NAFLD except for lifestyle medication.

Indexed as

fucoxanthinlipid-lowering bioactivitymicroalgal extractnon-alcoholic fatty liver disease

Identifiers

PMID34681228
PMCPMC8538132
OpenAlexW3202962880

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.